Record growth at The Wasdell Group

7 Nov 2018

Despite Brexit looming, the company's EU & UK business has increased by almost 30% in the last 12 months.

The Wasdell Group, an outsourcing partner for the pharmaceutical, medical device and clinical development and manufacturing industries, has experienced over 40% revenue growth in the last 24 months, following an increase in demand for its clinical trial, manufacturing and packing services.

Record growth at The Wasdell Group

Wasdell enter the final quarter of 2018 with a revenue of £41M, a considerable increase compared with £28M in 2016. This record growth has allowed the company to expand its clinical development, manufacturing and packaging capabilities, as well as invest in an on-site laboratory and build its first site outside of the UK.

Martin Tedham, CEO at The Wasdell Group said: “Our strong growth can be largely attributed to the number of pre-clinical development projects that we have recently been awarded, as well as our ongoing work in our manufacturing division.

“It is clear we are becoming more established across the pharmaceutical sector for our efficient service and ability to support customers with end-to-end supply needs. We are not only receiving an influx of new business, but more of our customers are also recognising the advantages of outsourcing more of their operations to Wasdell.”

Following the completion of building work on its new site in Dundalk, Ireland – due to finish in spring 2019 – the company will add 300 new members of staff to its team talking the total number of employees to 1000.

Martin continued: “Despite Brexit looming, our EU & UK business has increased by almost 30% in the last 12 months. We have also strengthened our partnerships with a number of US customers as a result of futureproofing our position as a reliable stepping stone into European market.

“Looking back to 2009 we were turning over just under £2m so to hit our £40M target fills me with a huge amount of pride and gratitude to our customers and our employees. I believe the customer-centric approach Wasdell has always taken, whether it be in delivery of our work or in the investments we have made, has played a huge part in our success today. I can’t wait to see what the future holds.”

Wasdell has ongoing plans to continue investing in its manufacturing and distribution facilities across the UK, especially at its Swindon site which is set to expand in 2019. This next round of investment will cater for the company’s forecasted growth which is estimated to increase by a further 25% by 2020.

Read More

Related news

New HCP Kit for automated impurity analysis of biotherapeutics

New HCP Kit for automated impurity analysis of biotherapeutics

21 Jun 2019

Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows.

Read more 
Sanofi and Google to develop new healthcare Innovation Lab

Sanofi and Google to develop new healthcare Innovation Lab

20 Jun 2019

Collaboration aims to change how Sanofi develops new treatments and will focus on to better understand patients and diseases, to increase Sanofi’s operational efficiency, and to improve the experience of Sanofi’s patients and customers.

Read more 
Catalent to purchase BMS manufacturing facility

Catalent to purchase BMS manufacturing facility

19 Jun 2019

Customers to have access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more 
Colorcon launches Opadry Enteric for use with hydro-alcoholic media

Colorcon launches Opadry Enteric for use with hydro-alcoholic media

17 Jun 2019

A fully formulated one-step system providing simple preparation and ease-of-use for film coating.

Read more 
SenzaGen granted its first patent for GARD potency biomarker test

SenzaGen granted its first patent for GARD potency biomarker test

16 Jun 2019

Company can now offer an animal-free test method to quantify the strength of an allergenic effect.

Read more 
Affordable measles and rubella vaccines using NevoLine manufacturing platform

Affordable measles and rubella vaccines using NevoLine manufacturing platform

14 Jun 2019

Univercells' propriety bioproduction platform has already proven success.

Read more 
Leaf Expression Systems launches first line of Hypertrans research products

Leaf Expression Systems launches first line of Hypertrans research products

13 Jun 2019

Plant-expression deal for difficult to produce proteins, vaccines, metabolites and natural proteins.

Read more 
Clinical supply milestone reached for triple-negative breast cancer treatment

Clinical supply milestone reached for triple-negative breast cancer treatment

12 Jun 2019

PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.

Read more 
Combining IT and OT software to solve manufacturing’s most frequent challenges

Combining IT and OT software to solve manufacturing’s most frequent challenges

11 Jun 2019

PTC and Rockwell Automation combine technologies to accelerate customers’ digital transformation initiatives.

Read more